Patents Represented by Attorney Laura A. Donnelly
-
Patent number: 8290581Abstract: The present invention is directed to an apparatus that includes a microcurrent delivery device portion and at least one independent sensory cue delivery means. The independent sensory cue delivery means can provide an independent sensory cue selected from the group consisting of vibration, heat, cool, skin irritation, tingling, fragrance or auditory.Type: GrantFiled: October 30, 2008Date of Patent: October 16, 2012Assignee: McNeil-PPC, Inc.Inventors: Leo B. Kriksunov, Aliya Z. Omer, Edward Roche, Joshua Ghaim, Naomi Furgiuele
-
Patent number: 8211465Abstract: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.Type: GrantFiled: February 7, 2012Date of Patent: July 3, 2012Assignee: McNeil-PPC, Inc.Inventors: Der-Yang Lee, Frank Bunick, James Schwing
-
Patent number: 8183290Abstract: The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs. In particular a 2:1 complex of naproxen sodium to propylene glycol is disclosed which is a crystalline solid. The complex is prepared by crystallization of a mixture of naproxen sodium and propylene glycol from diethyl ether. It is identifiable by its X-ray powder diffraction pattern described herein.Type: GrantFiled: July 20, 2010Date of Patent: May 22, 2012Assignee: McNeil-PPC, Inc.Inventors: Mark Tawa, Örn Almarsson, Julius Remenar
-
Patent number: 8137694Abstract: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, is provided. The inventive dosage forms provide an initial release of the NSAID and a second sustained release of NSAID, preferably in a single dosing step.Type: GrantFiled: August 15, 2007Date of Patent: March 20, 2012Assignee: McNeil-PPC, Inc.Inventors: Der-Yang Lee, Frank Bunick, James Schwing
-
Patent number: 8114328Abstract: Systems, methods and apparatuses for manufacturing dosage forms, and to dosage forms made using such systems, methods and apparatuses are provided. Novel compression, thermal cycle molding, and thermal setting molding modules are disclosed. One or more of such modules may be linked, preferably via novel transfer device, into an overall system for making dosage forms.Type: GrantFiled: August 4, 2004Date of Patent: February 14, 2012Assignee: McNeil-PPC, Inc.Inventors: Harry S. Sowden, Bernard F. Plantz, Shun Por Li
-
Patent number: 8067029Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.Type: GrantFiled: July 23, 2004Date of Patent: November 29, 2011Assignee: McNeil-PPC, Inc.Inventors: Roger A. Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollock, Atul Ayer, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
-
Patent number: 8057820Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated granule comprising an intimate mixture of an aspirin active ingredient and at least one binder capable of preferentially absorbing ambient moisture.Type: GrantFiled: October 8, 2004Date of Patent: November 15, 2011Assignee: McNeil-PPC, Inc.Inventors: Manoj N. Shah, James S. Beahm, Robert Shen
-
Patent number: 7972624Abstract: In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches and combinations thereof, and the matrix is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. The dosage form may additionally comprise uncoated particles which may contain at least one active ingredient. In another embodiment, a dosage form comprises at least one active ingredient, a plurality of particles and a molded matrix, wherein at least a portion of the particles are coated.Type: GrantFiled: February 24, 2009Date of Patent: July 5, 2011Inventors: Shun-Por Li, Harry S. Sowden, David Wynn, Der-Yang Lee, Martin Thomas
-
Patent number: 7968120Abstract: In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches and combinations thereof, and the matrix is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. The dosage form may additionally comprise uncoated particles which may contain at least one active ingredient. In another embodiment, a dosage form comprises at least one active ingredient, a plurality of particles and a molded matrix, wherein at least a portion of the particles are coated.Type: GrantFiled: September 28, 2002Date of Patent: June 28, 2011Assignee: McNeil-PPC, Inc.Inventors: Shun-Por Li, Harry S Sowden, David Wynn, Der-Yang Lee, Martin Thomas
-
Patent number: 7838026Abstract: A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C. and at least one carrageenan is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, to provide burst release of active ingredient contained therein.Type: GrantFiled: October 28, 2003Date of Patent: November 23, 2010Assignee: McNeil-PPC, Inc.Inventors: Shun-Por Li, Der-Yang Lee, Frank J. Bunick, Jen Chi Chen, Harry S. Sowden
-
Patent number: 7734371Abstract: The present invention is directed to a vending system or automated store and method of practice that has a means for inputting data, e.g., data input device, means for analyzing the data, e.g., microprocessor, and an output based on the analysis that includes information, product, or both. The invention is particularly suited for the delivery of healthcare and/or personal care products. The system provides a prospective consumer with information about products and their use, and preferably is capable of accessing qualified savings accounts for purposes of completing a transaction.Type: GrantFiled: September 13, 2006Date of Patent: June 8, 2010Assignee: McNeil-PPC, Inc.Inventor: Leo J Garneau, III
-
Patent number: 7635490Abstract: The invention provides a dosage form comprising at least one active ingredient, and first core and second cores surrounded by and separated by a shell. The dosage form provides a delay of at least one hour between the initial release of active ingredient contained in said first core and the initial release of active ingredient contained in said second core after contacting of the dosage form with a liquid medium.Type: GrantFiled: March 21, 2003Date of Patent: December 22, 2009Assignee: McNeil-PPC, Inc.Inventors: David Wynn, Gerard P. McNally, Harry S. Sowden
-
Patent number: 7615533Abstract: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.Type: GrantFiled: February 14, 2006Date of Patent: November 10, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Edward J. Yurkow, Brian R. MacDonald, Jeffery K. Weis
-
Patent number: 7579356Abstract: The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.Type: GrantFiled: April 10, 2006Date of Patent: August 25, 2009Assignee: Janssen Pharmaceutica NVInventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Stuart Hayden, Sigmond G. Johnson, Ronghui Lin, Niranjan B. Pandey, Mark T. Powell
-
Patent number: 7576056Abstract: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.Type: GrantFiled: August 13, 2004Date of Patent: August 18, 2009Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Brian R. MacDonald, Jeffery Kenneth Weis, Edward John Yurkow
-
Patent number: 7575888Abstract: It is now discovered that human chymase cleaves human SLPI at a specific site and that this cleavage can be used as an indicator of chymase activity. The present invention provides methods of diagnosing a chymase-associated disease or evaluating the efficiency of a treatment of a chymase-associated disease in a human subject by measuring SLPI processing, as well as other related methods and compositions.Type: GrantFiled: January 12, 2007Date of Patent: August 18, 2009Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Stanley Belkowski, Michael R. D'Andrea
-
Patent number: 7575882Abstract: It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.Type: GrantFiled: October 30, 2006Date of Patent: August 18, 2009Assignee: Janssen Pharmaceutica N. V.Inventors: Ning Qin, Yi Liu, Christopher M. Flores, Tasha Hutchinson, Michael P. Neeper
-
Patent number: 7563922Abstract: Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile of formula (I), a N-oxide, a pharmaceutically acceptable acid addition salt, a quaternary amine or a stereochemically isomeric form thereof are provided, said processes comprise: a) reacting 4-(2-cyanoethenyl)-2,6-dimethylbenzenamine with an intermediate of formula (III) ?in the presence of a suitable solvent; b) reacting an intermediate of formula (IV) ?with acrylonitrile in the presence of a suitable palladium catalyst, a suitable base and a suitable solvent; c) dehydrating the corresponding amide of the compound of formula (I).Type: GrantFiled: April 23, 2007Date of Patent: July 21, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Didier Philippe Robert Schils, Joannes Josephus Maria Willems, Bart Petrus Anna Maria Jozef Medaer, Elisabeth Therese Jeanne Pasquier, Paul Adriaan Jan Janssen, Jan Heeres, Ruben Gerardus George Leenders, Jérôme Emile Georges Guillemont
-
Patent number: 7541367Abstract: The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.Type: GrantFiled: May 31, 2006Date of Patent: June 2, 2009Assignee: Janssen Pharmaceutica, N.V.Inventors: George Chiu, Peter J. Connolly, Stuart Emanuel, Shenlin Huang, Shengjian Li, Ronghui Lin, Yanhua Lu, Steven A. Middleton
-
Patent number: 7541476Abstract: The present invention provides a radiolabeled astemizole of formula (III) and a process for preparing the radiolabeled astemizole of formula III.Type: GrantFiled: January 26, 2007Date of Patent: June 2, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Godelieve Irma Christine Maria Heylen, Cornelus Gerardus Maria Janssen, Jurzak Mirek, Henricus Petrus Martinus Maria Van Assouw